Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 4,387,198	$ 5,478,113
Research and development tax incentive receivable	400,881	433,852
Prepaid assets and other current assets	1,092,096	1,678,353
Total current assets	5,880,175	7,590,318
Operating lease right-of-use asset, net	78,924	119,529
Property and equipment, net	1,759,611	1,999,781
Investment in Vaxanix	1,776,746
Note receivable - Augmenta		2,310,000
Other assets		7,688
Total assets	9,495,456	12,027,316
Current liabilities:
Accounts payable	1,358,876	958,442
Accrued liabilities	2,160,140	1,285,586
Deferred research grant revenue	25,000	101,000
Current portion of operating lease liability	74,124	83,512
Total current liabilities	3,618,140	2,428,540
Operating lease liability, net of current portion		31,742
Total liabilities	3,618,140	2,460,282
Commitments and contingencies (see Note 5)
Stockholders’ equity:
Common stock; $0.001 par value, 180,000,000 shares authorized; 3,245,610 and 2,370,000 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively	3,246	2,370
Additional paid-in capital	134,604,851	128,044,509
Accumulated other comprehensive loss	(184,763)	(148,192)
Accumulated deficit	(128,546,018)	(118,331,653)
Total stockholders’ equity	5,877,316	9,567,034
Total liabilities and stockholders’ equity	$ 9,495,456	$ 12,027,316